Precision Diagnostics & Island Hospital Penang Formalise Strategic MOU to advance PGx & NGx Services
Precision Diagnostics is proud to announce the signing of a Memorandum of Understanding (MOU) with Island Hospital Penang, marking a significant step forward in the integration of Pharmacogenomics (PGx) and Nutrigenomics (NGx) into clinical services.
From previous trainings and sessions, until this collaboration, Island Hospital Penang will adopt Precision Diagnostics’ PGx and NGx testing to support more personalised, evidence-based clinical decision-making, helping clinicians optimise medication selection, dosing strategies, and nutrition recommendations based on individual genetic profiles.
The MOU signing was witnessed by key leaders from Island Hospital Penang:
- Dr Koo Jian Wei, Chief Operating Officer
- Mr Chuah Chong Chew, Director of Diagnostic
- Ms Julie Onn, Laboratory Manager
This partnership reflects a shared commitment to advancing precision medicine by moving beyond a one-size-fits-all approach, and towards care that is tailored to each patient’s genetic makeup.
By combining Island Hospital Penang’s clinical expertise with Precision Diagnostics’ clinically validated PGx and NGx solutions, this collaboration aims to enhance treatment safety, improve therapeutic outcomes, and set a new benchmark for personalised healthcare delivery in Malaysia.
Recent Events
